Cannas Valeria, Daino Gian Luca, Corona Angela, Esposito Francesca, Tramontano Enzo
Department of Life and Environmental Sciences, University of Cagliari, Italy.
J Infect Dis. 2015 Oct 1;212 Suppl 2:S277-81. doi: 10.1093/infdis/jiv214. Epub 2015 Apr 29.
During Ebola virus (EBOV) infection, the type I interferon α/β (IFN-α/β) innate immune response is suppressed by EBOV viral protein 35 (VP35), a validated drug target. Identification of EBOV VP35 inhibitors requires a cellular system able to assess the VP35-based inhibitory functions of viral double-stranded RNA (dsRNA) IFN-β induction. We established a miniaturized luciferase gene reporter assay in A549 cells that measures IFN-β induction by viral dsRNA and is dose-dependently inhibited by VP35 expression. When compared to influenza A virus NS1 protein, EBOV VP35 showed improved inhibition of viral dsRNA-based IFN-β induction. This assay can be used to screen for EBOV VP35 inhibitors.
在埃博拉病毒(EBOV)感染期间,I型干扰素α/β(IFN-α/β)先天免疫反应受到EBOV病毒蛋白35(VP35)的抑制,VP35是一个经过验证的药物靶点。鉴定EBOV VP35抑制剂需要一个能够评估基于VP35的病毒双链RNA(dsRNA)诱导IFN-β抑制功能的细胞系统。我们在A549细胞中建立了一种小型化荧光素酶基因报告试验,该试验可测量病毒dsRNA诱导的IFN-β,并且VP35的表达对其具有剂量依赖性抑制作用。与甲型流感病毒NS1蛋白相比,EBOV VP35对基于病毒dsRNA的IFN-β诱导的抑制作用更强。该试验可用于筛选EBOV VP35抑制剂。